ER+/HER2- breast cancer
Keytruda’s Success in KEYNOTE-756 Trial Ushers in a New Era for Early-Stage High-Risk ER+/HER2– Breast Cancer Treatment (ESMO 2023)
Anika Sharma
ESMO 2023: LBA21 Keytruda (pembrolizumab) is a highly specific, human-made antibody that targets the PD-1 pathway and prevents cancer cells ...
